US 12,433,927 B2
Therapeutic treatment for the coronavirus disease COVID-19
Peter Joseph Mollick, Phoenix, AZ (US)
Filed by Peter Joseph Mollick, Phoenix, AZ (US)
Filed on Nov. 11, 2023, as Appl. No. 18/388,823.
Application 18/388,823 is a division of application No. 18/104,030, filed on Jan. 31, 2023, granted, now 11,865,154.
Application 18/104,030 is a division of application No. 17/602,234, abandoned, previously published as PCT/US2021/025298, filed on Apr. 1, 2021.
Claims priority of provisional application 63/102,925, filed on Jul. 8, 2020.
Claims priority of provisional application 63/100,831, filed on Apr. 2, 2020.
Prior Publication US 2024/0075090 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 36/00 (2006.01); A61K 9/48 (2006.01); A61K 36/53 (2006.01)
CPC A61K 36/53 (2013.01) [A61K 9/4833 (2013.01)] 15 Claims
 
1. A method for a therapeutic treatment of a coronavirus disease Covid-19 in humans, the method comprises oral ingestion of an herb thyme used in a therapeutically effective dose or dosage regime.